Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Graham K. Morrell as Vice-President of Investors Relations & Communication, effective as from 13th of June 2016.

Mr. Morrell joins Celyad with extensive experience in investor relations management and institutional equity trading. Prior to Celyad, Graham was Senior Vice President for The Trout Group/Trout Capital LLC where he was responsible for leading investor relation and capital market strategies for life science companies. Graham holds a B.A. in Government from Harvard University.

Patrick Jeanmart, CFO of Celyad: “We are pleased to welcome Graham to our executive management team, where he brings over 15 years of expertise in financial markets and investor relations. Based on his strong experience in Investor Relations and his good knowledge of the biopharmaceutical industry, Graham will head the implementation of our Investor Relations strategy in the U.S.”.

Graham K. Morrell: “I am honored to be joining Celyad during this truly transformational period in its growth. I am excited to be part of an impressive team at Celyad and look forward to helping strengthen the company’s relationship with the investment community.”

Graham will be based in Boston, USA and will report to Patrick Jeanmart, Chief Financial Officer. 

Download press release(s)

Press release

169.96 Ko

Celyad treats first patient in the fourth dose level of its NKR-2 trial

Next News

Celyad treats first patient in the fourth dose level of its NKR-2 trial